Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
1996-7-18
|
pubmed:abstractText |
Two types of markers, namely the clone-specific markers including T-cell receptor (TCR) gamma, TCR delta, and Ig heavy-chain (IgH) gene rearrangements, and malignancy-specific fusion gene mRNA such as SIL-TAL-1, BCR-ABL, and HRX-partner genes, were investigated by molecular biology techniques in 65 Chinese patients with acute lymphoblastic leukemia (ALL). In combination, these markers were informative among 96% of patients. Minimal residual disease (MRD) was followed up in 23 of these patients with available materials over a period varying from 8 to 54 months with at least one leukemia-specific probe. In most children, MRD was decreased continuously to an ultimately undetectable level within 6 to 12 months after remission induction therapy. One patient exhibited low-level residual leukemic cells for 4 years before the MRD turned negative. Another patient remained in complete remission for 45 months, although a positive signal was detected at 34 months using TCR delta probe, but was negative with a TCR gamma marker which was positive at presentation. In three patients who relapsed, MRD either persisted through the clinical course or became positive and eventually increased 3-11 months before clinical relapse. These data suggested that the combined use of multiple gene markers is a valuable tool for the PCR-based MRD detection, since it can cover most ALL patients. Furthermore, long-term follow-up of MRD is helpful for determining the dosage as well as the period of maintenance chemotherapy and for predicting impending relapse.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
0165-4608
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
88
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
110-7
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:8640718-Base Sequence,
pubmed-meshheading:8640718-Burkitt Lymphoma,
pubmed-meshheading:8640718-Child,
pubmed-meshheading:8640718-Child, Preschool,
pubmed-meshheading:8640718-Female,
pubmed-meshheading:8640718-Follow-Up Studies,
pubmed-meshheading:8640718-Gene Rearrangement, delta-Chain T-Cell Antigen Receptor,
pubmed-meshheading:8640718-Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor,
pubmed-meshheading:8640718-Genetic Markers,
pubmed-meshheading:8640718-Humans,
pubmed-meshheading:8640718-Infant,
pubmed-meshheading:8640718-Leukemia-Lymphoma, Adult T-Cell,
pubmed-meshheading:8640718-Male,
pubmed-meshheading:8640718-Molecular Sequence Data,
pubmed-meshheading:8640718-Neoplasm, Residual,
pubmed-meshheading:8640718-Precursor Cell Lymphoblastic Leukemia-Lymphoma
|
pubmed:year |
1996
|
pubmed:articleTitle |
Long-term follow-up of minimal residual disease in childhood acute lymphoblastic leukemia patients by polymerase chain reaction analysis of multiple clone-specific or malignancy-specific gene markers.
|
pubmed:affiliation |
Shanghai Institute of Hematology, Rui-Jin Hospital, Shanghai Second Medical University (SSMU), China.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|